Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05070845 | Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia | PHASE2 | RECRUITING | 91 | — | — | Feb 2, 2022 | Aug 2, 2028 | May 12, 2026 | 31 | United States, Australia +5 |
To evaluate absolute value of platelet count of treated participants
| Arm | Type | Description |
|---|---|---|
| Open Label PF-06835375 dose 1 Treatment | EXPERIMENTAL | subcutaneous injection once monthly for 3 months |
| Open Label PF-06835375 dose 2 Treatment | EXPERIMENTAL | subcutaneous injection once monthly for 4 months |
| Open Label PF-06835375 dose 3 Treatment | EXPERIMENTAL | subcutaneous injection once monthly for 4 months |
| Open Label PF-06835375 dose 4 Treatment | EXPERIMENTAL | subcutaneous injections once monthly for 4 months |
| Name | Type | Description |
|---|---|---|
| PF-06835375 | BIOLOGICAL | CXCR5 inhibitor |
Inclusion Criteria: * Diagnosis of Primary ITP. Ongoing ITP (platelet counts \<50 x 109/L) \[No severe bleeding within 1 month or during screening\] AND Persistent ITP (3 to 12 months) or Chronic ITP \>12 months Exclusion Criteria: * Bleeding event according to the WHO grading scale ≥2 occurring ...